Veru (VERU)
(Delayed Data from NSDQ)
$1.27 USD
+0.06 (4.96%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VERU 1.27 +0.06(4.96%)
Will VERU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VERU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERU
What Makes Veru (VERU) a New Buy Stock
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
VERU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
Charles River (CRL) to Report Q4 Earnings: What's in Store?
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Other News for VERU
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
LI, VERU and MRIN among pre-market losers
Veru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare movers
Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers
Truist healthcare analyst to hold an analyst/industry conference call